Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: Gamma-imaging studies

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 10, 2006, Pages 1196-1205

  Elbayoumi, Tamer A ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Anticancer monoclonal antibody; Gamma scintigraphy; Long circulating liposomes; Nucleosome; Tumour targeting

Indexed keywords

INDIUM 111; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C5; NUCLEOSOME ANTIBODY; PENTETIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ENGINEERING; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL LABELING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOSOME; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; FEMALE; INDIUM RADIOISOTOPES; LIPOSOMES; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NUCLEOSOMES; ORGAN SPECIFICITY; RADIONUCLIDE IMAGING; TISSUE DISTRIBUTION;

EID: 33749255196     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0139-x     Document Type: Article

References (32)

1. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-160
2. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268:235-237
3. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-11464
4. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29-36
5. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207
6. Torchilin VP. Liposomes as delivery agents for medical imaging. Mol Med Today 1996;2:242-249
7. Phillips WT. Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev 1999;37:13-32
8. Tilcock C, Unger E, Cullis P, MacDougall P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology 1989;171:77-80
9. Kabalka GW, Davis MA, Moss TH, Buonocore E, Hubner K, Holmberg E, et al. Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn Reson Med 1991;19:406-415
10. Schwendener RA, Wuthrich R, Duewell S, Wehrli E, von Schulthess GK. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest Radiol 1990;25:922-932
11. Harrington KJ. Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin Investig Drugs 2001;10:1045-1061
12. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7:243-254
13. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-496
14. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999;17:3512-3521
15. Stewart SS, Harrington KJ. The biodistribution and pharmacokinetics of Stealth liposomes in patients with solid tumors. Oncology 1997;33-37
16. Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 2001;37:2015-2022
17. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000; 83:1281-1286
18. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - rationale for combination with radiotherapy. Acta Oncol 2000;39:207-211
19. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-763.
20. Iakoubov LZ, Rokhlin O, Torchilin VP. Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Immunol Lett 1995;47:147-149
21. Iakoubov LZ, Torchilin VP. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol Res 1997;9:439-446
22. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol 2001;22:424-427
23. Chakilam AR, Pabba S, Mongayt D, Iakoubov LZ, Torchilin VP. A single monoclonal antinuclear autoantibody with nucleosome-restricted specificity inhibits the growth of diverse human tumors in nude mice. Cancer Therapy 2004;2:353-364
24. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 2003;100:6039-6044
25. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 2004;100:135-144
26. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw, BA, Klibanov AL, Rammohan R, et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 2001;1511:397-411
27. Kabalka GW, Davis MA, Holmberg E, Maruyama K, Huang L. Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver. Magn Reson Imaging 1991;9:373-377
28. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1999;460:129-133
29. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63:86-92
30. Sou K, Endo T, Takeoka S, Tsuchida E. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem 2000;11:372-379
31. Brignole C, Marimpietri D, Gambini C, Allen TM, Ponzoni M, Pastorino F. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett 2003;197:199-204
32. Klibanov AL, Muzykantov VR, Ivanov NN, Torchilin VP. Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. Anal Biochem 1985;150:251-257